Acceleron Pharma Inc. (XLRN) Reaches $45.12 52-Week High; Terra Nitrogen Co LP (TNH)’s Sentiment Is 0.83

January 14, 2018 - By Marie Mckinney

The stock of Acceleron Pharma Inc. (NASDAQ:XLRN) hit a new 52-week high and has $48.28 target or 7.00% above today’s $45.12 share price. The 7 months bullish chart indicates low risk for the $2.04 billion company. The 1-year high was reported on Jan, 14 by Barchart.com. If the $48.28 price target is reached, the company will be worth $142.87M more. The stock increased 2.76% or $1.21 during the last trading session, reaching $45.12. About 666,831 shares traded or 114.63% up from the average. Acceleron Pharma Inc. (NASDAQ:XLRN) has declined 22.43% since January 14, 2017 and is downtrending. It has underperformed by 39.13% the S&P500.

Terra Nitrogen Company, L.P. produces nitrogen fertilizer products in the United States. The company has market cap of $1.64 billion. It primarily offers anhydrous ammonia and urea ammonium nitrate solutions for farmers to enhance the yield and quality of their crops. It has a 13.64 P/E ratio. The firm sells its fertilizer products to an affiliate of Terra Nitrogen GP Inc.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. The company has market cap of $2.04 billion. The Company’s therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. It currently has negative earnings. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy.

Investors sentiment increased to 1.81 in Q3 2017. Its up 0.37, from 1.44 in 2017Q2. It increased, as 12 investors sold Acceleron Pharma Inc. shares while 30 reduced holdings. 30 funds opened positions while 46 raised stakes. 37.73 million shares or 12.48% more from 33.54 million shares in 2017Q2 were reported. Legal & General Group Inc Public Limited Liability Corp has invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Sectoral Asset invested in 604,957 shares or 2.91% of the stock. Envestnet Asset Mgmt has 653 shares for 0% of their portfolio. Swiss National Bank invested in 62,300 shares. Ameritas Inv Prtn Incorporated stated it has 2,813 shares. Ray Gerald L Associates Ltd has 8,600 shares. Parallax Volatility Advisers Limited Partnership accumulated 5,208 shares. 43,244 were accumulated by Wells Fargo & Co Mn. Tiaa Cref Inv Management Lc reported 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). State Of Wisconsin Inv Board reported 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Bank Of Montreal Can invested 0% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN). Moreover, Vanguard Gru has 0% invested in Acceleron Pharma Inc. (NASDAQ:XLRN). Prudential Inc owns 81,010 shares. Fosun reported 0% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN). Utd Automobile Association accumulated 91,480 shares.

Among 16 analysts covering Acceleron Pharma (NASDAQ:XLRN), 11 have Buy rating, 1 Sell and 4 Hold. Therefore 69% are positive. Acceleron Pharma has $63 highest and $20 lowest target. $44.07’s average target is -2.33% below currents $45.12 stock price. Acceleron Pharma had 35 analyst reports since August 13, 2015 according to SRatingsIntel. The company was maintained on Friday, June 23 by FBR Capital. UBS maintained the shares of XLRN in report on Tuesday, September 12 with “Buy” rating. The firm earned “Overweight” rating on Wednesday, September 20 by Barclays Capital. Citigroup initiated the stock with “Neutral” rating in Thursday, September 29 report. The stock has “Market Perform” rating by Oppenheimer on Tuesday, June 13. The company was initiated on Thursday, August 13 by Morgan Stanley. Oppenheimer initiated it with “Outperform” rating and $58 target in Friday, November 20 report. Barclays Capital maintained the shares of XLRN in report on Monday, June 13 with “Overweight” rating. The firm earned “Overweight” rating on Wednesday, April 27 by Barclays Capital. The rating was maintained by FBR Capital with “Buy” on Tuesday, June 13.

Since August 8, 2017, it had 1 buying transaction, and 12 insider sales for $19.64 million activity. Another trade for 4,633 shares valued at $197,868 was made by Sherman Matthew L on Wednesday, January 3. 16,000 Acceleron Pharma Inc. (NASDAQ:XLRN) shares with value of $614,546 were sold by MCLAUGHLIN KEVIN F. Another trade for 2,266 shares valued at $96,134 was sold by Rovaldi Christopher. George Jean had sold 105,122 shares worth $3.76 million. Another trade for 13,065 shares valued at $462,632 was made by Kumar Ravindra on Tuesday, August 8. 4,333 shares valued at $183,806 were sold by Quisel John D on Tuesday, January 2. CELGENE CORP /DE/ bought $27.59 million worth of stock.

Analysts await Acceleron Pharma Inc. (NASDAQ:XLRN) to report earnings on March, 7. They expect $-0.60 EPS, down 17.65% or $0.09 from last year’s $-0.51 per share. After $-0.65 actual EPS reported by Acceleron Pharma Inc. for the previous quarter, Wall Street now forecasts -7.69% EPS growth.

The stock decreased 0.20% or $0.17 during the last trading session, reaching $86.81. About 29,173 shares traded or 0.84% up from the average. Terra Nitrogen Company, L.P. (TNH) has declined 16.55% since January 14, 2017 and is downtrending. It has underperformed by 33.25% the S&P500.

Bridgecreek Investment Management Llc holds 1.13% of its portfolio in Terra Nitrogen Company, L.P. for 50,815 shares. S&T Bank Pa owns 32,138 shares or 0.47% of their US portfolio. Moreover, Bowen Hanes & Co Inc has 0.4% invested in the company for 103,400 shares. The Texas-based U S Global Investors Inc has invested 0.35% in the stock. Horizon Kinetics Llc, a New York-based fund reported 23,586 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.